ECSP066384A - Proceso para la preparación de 4-amino - 3- quinolincarbonitrilos - Google Patents

Proceso para la preparación de 4-amino - 3- quinolincarbonitrilos

Info

Publication number
ECSP066384A
ECSP066384A EC2006006384A ECSP066384A ECSP066384A EC SP066384 A ECSP066384 A EC SP066384A EC 2006006384 A EC2006006384 A EC 2006006384A EC SP066384 A ECSP066384 A EC SP066384A EC SP066384 A ECSP066384 A EC SP066384A
Authority
EC
Ecuador
Prior art keywords
amino
cyanoacetamide
produce
preparation
cyanoacrylamide
Prior art date
Application number
EC2006006384A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Sutherland Karen Wiggins
Gregg Brian Feigelson
David Michael Blum
Henry Lee Strong
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34215972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066384(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066384A publication Critical patent/ECSP066384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Esta invención describe un proceso para la preparación de 4-amino-3-quinolincarbonitrilo, que comprende combinar un compuesto de amina con un ácido cianoacético y un catalizador ácido, para producir una cianoacetamida; condensar la cianoacetamida con una anilina opcionalmente hasta tetra-sustituida, en un solvente alcohólico y un ortoformiato de trialquilo, para producir una 2-amino-2-cianoacrilamida; combinar la 3-amino-2-cianoacrilamida con oxicloruro de fósforo en acetonitrilo, butironitrilo, tolueno o xileno, opcionalmente en presencia de un catalizador, para producir el 4-amino-3-quinolincarbonitrilo, y también describe un proceso para la preparación del 7-amino-tieno[3,2-b]piridin-6-carbonitrilo, que comprende combinar un 3-amino-tiofeno con un cianoacetamida y ortoformiato de trialquilo en un solvente alcohólico, para obtener una 3-amino-2-cianoacrilamida; y combinar la 3-amino-2-cianoacrilamida con oxicloruro de fósforo y acetonitrilo, butironitrilo, tolueno o xileno, opcionalmente en presencia de un catalizador, para producir el 7-amino-tieno[3,2-b]piridin-6-carbonitrilo; y también describe un proceso para la preparación del 4-amino-3-quinolincarbonitrilo que comprende: combinar un compuesto de amina con ácido cianoacético con un reactivo de acoplamiento de péptidos, para obtener una suspensión; se filtra la suspensión; para producir la cianoacetamida; se condensa la cianoacetamida con una anilina opcionalmente hasta tetra-sustituida, con un solvente alcohólico para producir un 4-amino-3-quinolincarbonitrilo; y la invención describe un proceso para obtener una cianoacetamida.
EC2006006384A 2003-08-19 2006-02-17 Proceso para la preparación de 4-amino - 3- quinolincarbonitrilos ECSP066384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49619103P 2003-08-19 2003-08-19

Publications (1)

Publication Number Publication Date
ECSP066384A true ECSP066384A (es) 2006-08-30

Family

ID=34215972

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006384A ECSP066384A (es) 2003-08-19 2006-02-17 Proceso para la preparación de 4-amino - 3- quinolincarbonitrilos

Country Status (25)

Country Link
US (2) US7297795B2 (es)
EP (1) EP1660453A2 (es)
JP (1) JP2007502819A (es)
KR (1) KR20060066733A (es)
CN (1) CN1835923A (es)
AR (1) AR045277A1 (es)
AU (1) AU2004267061A1 (es)
BR (1) BRPI0413667A (es)
CA (1) CA2535385A1 (es)
CO (1) CO5670369A2 (es)
CR (1) CR8226A (es)
EC (1) ECSP066384A (es)
GT (1) GT200400165A (es)
IL (1) IL173456A0 (es)
MX (1) MXPA06001590A (es)
MY (1) MY140542A (es)
NO (1) NO20060539L (es)
PA (1) PA8609301A1 (es)
PE (1) PE20050344A1 (es)
RU (1) RU2345069C2 (es)
SA (1) SA04250258B1 (es)
SG (1) SG145744A1 (es)
SV (1) SV2005001855A (es)
TW (1) TW200517378A (es)
WO (1) WO2005019201A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479561B2 (en) 2004-08-16 2009-01-20 Wyeth 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1888529A2 (en) * 2005-05-18 2008-02-20 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
BRPI0610147A2 (pt) * 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
WO2007005462A1 (en) 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
AU2007212756A1 (en) * 2006-02-08 2007-08-16 Wyeth Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction
CN101195578B (zh) * 2006-12-08 2012-04-25 上海睿智化学研究有限公司 1-(卤烷氧基)-2-烷氧基-5-硝基苯类化合物的合成方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010030835A2 (en) * 2008-09-11 2010-03-18 Wyeth Llc Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
RU2011152105A (ru) 2009-07-02 2013-08-10 УАЙТ ЭлЭлСи Составы таблеток 3-цианохинолина и их применение
CN101792416B (zh) * 2010-01-15 2011-10-05 南京医科大学 一种博舒替尼的制备工艺
CA2803056C (en) * 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
CN104876865A (zh) * 2014-02-27 2015-09-02 南京正荣医药化学有限公司 一种博舒替尼的制备工艺
KR20220129667A (ko) 2015-07-06 2022-09-23 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
EP3319955B1 (en) * 2015-07-06 2020-11-25 Gilead Sciences, Inc. 6-amino-quinoline-3-carbonitrils as cot modulators
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
US11407734B2 (en) 2017-10-18 2022-08-09 Jiangsu Hengrui Medicine Co., Ltd. Preparation method for tyrosine kinase inhibitor and intermediate thereof
CN108084085B (zh) * 2017-12-28 2019-11-26 山东铂源药业有限公司 一种n-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法
WO2019186429A1 (en) * 2018-03-30 2019-10-03 Sun Pharmaceutical Industries Limited A process for the preparation of bosutinib
CN109180578B (zh) * 2018-10-19 2020-06-26 山东创新药物研发有限公司 一种博舒替尼的制备方法
CN111646955B (zh) * 2019-03-04 2024-05-24 鲁南制药集团股份有限公司 一种制备博舒替尼中间体的方法
CN111646939A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼的制备方法
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
KR102924836B1 (ko) 2020-03-30 2026-02-09 길리애드 사이언시즈, 인코포레이티드 Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція

Also Published As

Publication number Publication date
SG145744A1 (en) 2008-09-29
SV2005001855A (es) 2005-11-04
NO20060539L (no) 2006-02-13
KR20060066733A (ko) 2006-06-16
GT200400165A (es) 2005-04-12
RU2006108524A (ru) 2007-09-27
WO2005019201A3 (en) 2005-08-04
CA2535385A1 (en) 2005-03-03
CO5670369A2 (es) 2006-08-31
SA04250258B1 (ar) 2009-01-07
BRPI0413667A (pt) 2006-10-24
AU2004267061A1 (en) 2005-03-03
JP2007502819A (ja) 2007-02-15
AR045277A1 (es) 2005-10-19
RU2345069C2 (ru) 2009-01-27
MXPA06001590A (es) 2006-05-19
CR8226A (es) 2008-08-21
MY140542A (en) 2009-12-31
CN1835923A (zh) 2006-09-20
EP1660453A2 (en) 2006-05-31
PA8609301A1 (es) 2005-03-03
IL173456A0 (en) 2006-06-11
PE20050344A1 (es) 2005-06-19
TW200517378A (en) 2005-06-01
US20050043537A1 (en) 2005-02-24
US20080033175A1 (en) 2008-02-07
WO2005019201A2 (en) 2005-03-03
US7297795B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
AR045277A1 (es) Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos y 7 amino-tieno (3,2-b) piridin-6-carbonitrilos
WO2010125216A3 (es) Preparación de compuestos 5,6-dihidropirido[2,3-d]pirimidin-7(8h)-ona sustituidos
BR0207172A (pt) Pirido-pirimidinas 6-substituìdas
IN2014MN02582A (es)
BR0005636A (pt) Método para a produção de 4-carboxiamino-1,2,3,4-tetrahidroquinolina 2-substituìda
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
DE602004024545D1 (de) Indungen
CY1111227T1 (el) Mεθοδος παρασκευης 1-υποκατασταθεισων ενωσεων 1η-ιμιδαζο[4,5-c]κινολιν-4-αμινης και ενδιαμεσα γι' αυτην.
DK1567482T3 (da) Fremgangsmåde til fremstilling af phenylmalonsyre-dinitriler
DE60225953D1 (de) Verfahren zur Herstellung von Polyamid
WO2012087888A3 (en) Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (g) quinazoline trisodium salt
DE60119595D1 (de) Verfahren zur Herstellung von Polyamid
DE60110360D1 (de) Verfahren zur Herstellung von Polyamid
DK1353930T3 (da) Fremgangsmåde til fremstilling af N-phosphonomethyliminodieddikesyre
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
ATE331814T1 (de) Sicherheitssystem
DK1174418T3 (da) Fremgangsmåde til fremstilling af vandfrit gabapentin af farmaceutisk kvalitet
BR0305100A (pt) Processo para a preparação de olanzapina
GB0706558D0 (en) Diagnostic assay
DE502005004039D1 (de) Verfahren zur herstellung hochmolekularer polyamide
DE602004022857D1 (de) 2-methyl-6-solanylbenzochinon-methyltransferase als ziel für herbizide
WO2006035273A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
DK1438286T3 (da) Fremgangsmåde til fremstilling af arylsulfonsyreisocyanater
WO2006083983A3 (en) Bridgehead radiolabelled compounds and methods of using the same
TH124675A (es)